Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-

  • STATUS
    Recruiting
  • End date
    Jan 10, 2029
  • participants needed
    304
  • sponsor
    St. Petersburg State Pavlov Medical University
Updated on 27 January 2021
gastrectomy
renal function
fluorouracil
doxorubicin
oxaliplatin
neutrophil count
leucovorin
docetaxel
laparoscopy
cancer chemotherapy
adenocarcinoma
adjuvant chemotherapy
immunostimulants
peritoneal carcinomatosis

Summary

Stomach cancer is recognized as the third leading cause of death of cancer patients worldwide. Despite the radical treatment carried out, the progression of gastric cancer occurs in 30-40% of patients. The most common type of tumor progression of this localization is peritoneal carcinomatosis. When peritoneal carcinomatosis occurs, the median survival of patients does not exceed 3 months, the overall survival is no more than 6 months. Unfortunately, when peritoneal carcinomatosis occurs, palliative chemotherapy remains the only treatment option. The modern strategy for the prevention and treatment of peritoneal carcinomatosis is based on the concept of regional chemotherapy. The main methods of regional chemotherapy are hyperthermic intraperitoneal chemotherapy (HIPEC) and Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC). PIPAC is a new technology for delivering chemotherapy drugs to tumor nodes on the surface of the peritoneum and allows the cytostatic to be evenly distributed over the abdominal cavity, increasing the depth of its penetration into tumor nodes due to the properties of aerosol and gradients of intra-abdominal and interstitial pressure. The method has a number of advantages over the HIPEC method: a large penetration depth of drugs, low trauma, the possibility of repeated use. We offer PIPAC for patients with locally advanced gastric cancer and a high risk of developing peritoneal carcinomatosis in an adjuvant mode in addition to standard treatment to prevent the development of carcinomatosis.

Description

The study is interventional: patients over 18 years of age with an established diagnosis of stomach cancer (c)T3-4N0-3M0 CYT- will be randomized into 2 groups using the envelope method. The control group will receive only neoadjuvant chemotherapy + gastrectomy/ distal subtotal resection with D2 lymph node dissection, the active comparison group - neoadjuvant chemotherapy + gastrectomy with D2 lymph node dissection + PIPAC (Cisplatin (7.5 mg / m) + Doxirubicin 1.5 mg / m2)). Will be assessed: overall survival, median survival, disease-free survival, quality of life of patients.

Details
Condition Abdominal Neoplasm, Abdominal Cancer, Neoplasm of unspecified nature of digestive system, Digestive System Neoplasms, Gastropathy, Stomach Discomfort, Gastric Cancer, Gastric Cancer, Stomach Cancer, Stomach Discomfort, Peritoneal Carcinomatosis, Gastric Carcinoma, Abdominal Cancer, Stomach Cancer, Digestive System Neoplasms, gastric cancers
Treatment docetaxel, Oxaliplatin, Leucovorin, 5-fluorouracil, Adjuvant chemotherapy, PIPAC, Staging Laparoscopy, Radical Surgery
Clinical Study IdentifierNCT04595929
SponsorSt. Petersburg State Pavlov Medical University
Last Modified on27 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically confirmed, medically operable, resectable stomach adenocarcinoma (cT3-4, any N category, M0)
No preceding cytotoxic or targeted therapy
No prior partial or complete tumor resection
Female and male patient 18 and 75 years. Female patient with childbearing potential needs to have a negative pregnancy test within 7 days prior to study start. Males and females of reproductive potential must agree to practice highly effective contraceptive measures during the study. Male patients must also agree to refrain from father a child during treatment and additionally to use a condom during treatment period. Their female partner of childbearing potential must also agree to use an adequate contraceptive measure
highly effective (i.e. failure rate of <1% per year when used consistently and correctly) methods: intravaginal and transdermal combined (estrogen and progestogen containing) hormonal contraception; injectable and implantable progestogen-only hormonal contraception; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence (complete abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments)
ECOG = 0-2
Exclusion of distant metastases by CT or MRI of abdomen, pelvis, and thorax, bone scan or MRI (if bone metastases are suspected due to clinical signs). Exclusion of the infiltration of any adjacent organs or structures by CT or MRI
Laparoscopic exclusion of peritoneal carcinomatosis at initial staging, before start of FLOT chemotherapy
Adequate hematological, hepatic and renal function parameters
Leukocytes 3000/mm, platelets 100,000/mm, neutrophil count (ANC) 1000/L Serum
creatinine 1.5 x upper limit of normal Bilirubin 1.5 x upper limit of normal
AST and ALT 3.0 x upper limit of normal, alkaline phosphatase 6 x upper limit
of normal For patients not receiving therapeutic anticoagulation: INR or aPTT
5 x ULN; for patients receiving therapeutic anticoagulation: stable
anticoagulant regimen
Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures

Exclusion Criteria

Patient without neoadjuvant therapy or those who received a neoadjuvant therapy other than FLOT
Known hypersensitivity against 5-FU, leucovorin, oxaliplatin, or docetaxel
Other known contraindications against, 5-FU, leucovorin, oxaliplatin, or docetaxel
Clinically significant active coronary heart disease, cardiomyopathy or congestive heart failure, NYHA III-IV
Clinically significant valvular defect
Criteria of primary unresectability, e.g
Radiologically documented evidence of major blood vessel invasion or invasion
of adjacent organs (T4b)
Patients with involved retroperitoneal (e.g. para-aortal, paracaval or
interaortocaval lymph nodes) or mesenterial lymph nodes (distant metastases!)
Other severe internal disease or acute infection
Peripheral polyneuropathy NCI Grade II
Patient has undergone major surgery within 28 days prior to enrollment except staging laparoscopy
Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or ascites
On-treatment participation in another interventional clinical study in the period 30 days prior to inclusion and during the study
Patient pregnant or breast feeding, or planning to become pregnant
Any other concurrent antineoplastic treatment including irradiation
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note